Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Feb 6, 2019
Company News
Management tracks: Astellas, Blueprint
...company in November to become CMO of Sigilon Therapeutics Inc. (Cambridge, Mass.). Rare disease company
ArTara
...
Read More
BioCentury
|
Jan 9, 2018
Company News
Management tracks: OncoMed, Neurocrine
...Roberts. Roberts was VP of R&D at Eli Lilly and Co. (NYSE:LLY). Rare disease company
ArTara
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Feb 6, 2019
Company News
Management tracks: Astellas, Blueprint
...company in November to become CMO of Sigilon Therapeutics Inc. (Cambridge, Mass.). Rare disease company
ArTara
...
Read More
BioCentury
|
Jan 9, 2018
Company News
Management tracks: OncoMed, Neurocrine
...Roberts. Roberts was VP of R&D at Eli Lilly and Co. (NYSE:LLY). Rare disease company
ArTara
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page